Prognostische und prädiktive molekulare Marker urologischer Tumoren
Standard
Prognostische und prädiktive molekulare Marker urologischer Tumoren. / Hartmann, K A; Schlomm, T; Bertz, S; Heinzelmann, J; Hölters, S; Simon, R; Stoehr, R; Junker, K.
In: UROLOGE, Vol. 53, No. 4, 01.04.2014, p. 491-500.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostische und prädiktive molekulare Marker urologischer Tumoren
AU - Hartmann, K A
AU - Schlomm, T
AU - Bertz, S
AU - Heinzelmann, J
AU - Hölters, S
AU - Simon, R
AU - Stoehr, R
AU - Junker, K
PY - 2014/4/1
Y1 - 2014/4/1
N2 - Molecular prognostic factors and genetic alterations as predictive markers for cancer-specific targeted therapies are used today in the clinic for many malignancies. In recent years, many molecular markers for urogenital cancers have also been identified. However, these markers are not clinically used yet. In prostate cancer, novel next-generation sequencing methods revealed a detailed picture of the molecular changes. There is growing evidence that a combination of classical histopathological and validated molecular markers could lead to a more precise estimation of prognosis, thus, resulting in an increasing number of patients with active surveillance as a possible treatment option. In patients with urothelial carcinoma, histopathological factors but also the proliferation of the tumor, mutations in oncogenes leading to an increasing proliferation rate and changes in genes responsible for invasion and metastasis are important. In addition, gene expression profiles which could distinguish aggressive tumors with high risk of metastasis from nonmetastasizing tumors have been recently identified. In the future, this could potentially allow better selection of patients needing systemic perioperative treatment. In renal cell carcinoma, many molecular markers that are associated with metastasis and survival have been identified. Some of these markers were also validated as independent prognostic markers. Selection of patients with primarily organ-confined tumors and increased risk of metastasis for adjuvant systemic therapy could be clinically relevant in the future.
AB - Molecular prognostic factors and genetic alterations as predictive markers for cancer-specific targeted therapies are used today in the clinic for many malignancies. In recent years, many molecular markers for urogenital cancers have also been identified. However, these markers are not clinically used yet. In prostate cancer, novel next-generation sequencing methods revealed a detailed picture of the molecular changes. There is growing evidence that a combination of classical histopathological and validated molecular markers could lead to a more precise estimation of prognosis, thus, resulting in an increasing number of patients with active surveillance as a possible treatment option. In patients with urothelial carcinoma, histopathological factors but also the proliferation of the tumor, mutations in oncogenes leading to an increasing proliferation rate and changes in genes responsible for invasion and metastasis are important. In addition, gene expression profiles which could distinguish aggressive tumors with high risk of metastasis from nonmetastasizing tumors have been recently identified. In the future, this could potentially allow better selection of patients needing systemic perioperative treatment. In renal cell carcinoma, many molecular markers that are associated with metastasis and survival have been identified. Some of these markers were also validated as independent prognostic markers. Selection of patients with primarily organ-confined tumors and increased risk of metastasis for adjuvant systemic therapy could be clinically relevant in the future.
KW - Adult
KW - Aged
KW - Carcinoma, Renal Cell
KW - Carcinoma, Transitional Cell
KW - Genetic Association Studies
KW - Humans
KW - Kidney
KW - Kidney Neoplasms
KW - Male
KW - Middle Aged
KW - Molecular Diagnostic Techniques
KW - Molecular Sequence Data
KW - Neoplasm Grading
KW - Polymorphism, Single Nucleotide
KW - Predictive Value of Tests
KW - Prognosis
KW - Prostate
KW - Prostatic Neoplasms
KW - Tumor Markers, Biological
KW - Urinary Bladder
KW - Urinary Bladder Neoplasms
KW - Urogenital Neoplasms
U2 - 10.1007/s00120-014-3442-3
DO - 10.1007/s00120-014-3442-3
M3 - SCORING: Zeitschriftenaufsatz
C2 - 24700189
VL - 53
SP - 491
EP - 500
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 4
ER -